Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Tokyo Stock Exchange  >  Chugai Pharmaceutical Co., Ltd.    4519   JP3519400000

CHUGAI PHARMACEUTICAL CO., LTD.

(4519)
  Report
SummaryChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsPress ReleasesOfficial PublicationsSector newsMarketScreener StrategiesAnalyst Recommendations

Chugai Pharmaceutical : Results from the Investigator-Initiated Phase I Study of RAF/MEK Inhibitor, CKI27 Published in the Lancet Oncology Online

10/30/2020 | 09:44am EST

TOKYO - Chugai Pharmaceutical Co., Ltd. (TOKYO: 4519; hereinafter 'Chugai') announced that results from the investigator-initiated phase I study of RAK/MEK inhibitor, CKI27 (VS-6766) conducted in the U.K. was published on October 28, 2020 (local time) in the online version of the Lancet Oncology.

CKI27 is out-licensed from Chugai to Verastem Oncology, a U.S.-based company.

'Intermittent schedules of the oral RAF-MEK inhibitor CH5126766/VS-6766 in patients with RAS/RAF-mutant solid tumours and multiple myeloma: a single-centre, open-label, phase 1 dose-escalation and basket dose-expansion study' https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(20)30464-2/fulltext

The study was an investigator-initiated study in patients with RAS/RAF-mutated solid tumors and multiple myeloma, conducted at The Institute of Cancer Research, London, and The Royal Marsden NHS Foundation Trust in the U.K. It consisted of two parts; 1) dose escalation part to determine the recommended dosage (29 patients) and 2) basket expansion part to investigate efficacy and safety of the recommended dosage determined in the dose escalation part (29 patients).

The recommended dosage were determined to be 4 mg/day twice weekly in the dose escalation part. In the subsequent basket expansion part, 7 of 26 evaluable patients (26.9%) achieved objective responses. All patients with KRAS-mutation had non-G12C mutations. The most common treatment-related adverse events occurred as grade 3 or higher based on CTCAE v4.0 (the Common Terminology Criteria for Adverse Events provided by the U.S. National Cancer Institute) was skin rash, which developed in 11 of 57 evaluable patients (19.3%). No treatment-related death occurred. The results of the study were announced in the 53rd American Society of Clinical Oncology Annual Meeting (June, 2017).

CKI27 (VS-6766) is a new oral RAF/MEK inhibitor. Under the global licensing agreement concluded in January, 2020, clinical development of CKI27 is being conducted by Verastem Oncology under the name of VS-6766.

Chugai, which aims at becoming a top innovator in the healthcare industry, continues to pursue science and proprietary technology and promote open innovation including collaboration with academia, to contribute for patients across the world through innovative drugs.

Contact:

Tomoko Shimizu

Tel: +81-3-3273-0881

Email: pr@chugai-pharm.co.jp

(C) 2020 Electronic News Publishing, source ENP Newswire

Stocks mentioned in the article
ChangeLast1st jan.
CHUGAI PHARMACEUTICAL CO., LTD. -0.80% 4931 End-of-day quote.46.76%
ROCHE HOLDING AG 0.85% 302.25 Delayed Quote.-4.55%
All news about CHUGAI PHARMACEUTICAL CO., LTD.
11/30Chugai Files Patent Infringement Lawsuit concerning Edirol Capsules
AQ
11/25Chugai and DeNA Jointly Launch 'Ring Again,' a Rheumatoid Arthritis Disease A..
AQ
11/20CHUGAI PHARMACEUTICAL : Receives the Best IR Award
AQ
11/18CHUGAI PHARMACEUTICAL : Selected for the First Time in the 'DJSI World,' a Globa..
AQ
11/06CHUGAI PHARMACEUTICAL : Contributes Fourteen Thousand Tons of CO2 Emission Reduc..
AQ
10/30CHUGAI PHARMACEUTICAL : Results from the Investigator-Initiated Phase I Study of..
AQ
10/29CHUGAI PHARMACEUTICAL : Contribution of Para-transit Vehicles to Welfare Service..
AQ
10/23CHUGAI PHARMACEUTICAL : Announces 2020 3rd Quarter Results
AQ
10/22Japan stocks end lower as firmer yen, U.S. political uncertainty weigh
RE
10/21Japanese shares fall on rising yen, U.S. political uncertainty
RE
More news
Financials
Sales 2020 762 B 7 315 M 7 315 M
Net income 2020 216 B 2 071 M 2 071 M
Net cash 2020 403 B 3 864 M 3 864 M
P/E ratio 2020 37,7x
Yield 2020 1,07%
Capitalization 8 106 B 77 792 M 77 790 M
EV / Sales 2020 10,1x
EV / Sales 2021 9,13x
Nbr of Employees 7 394
Free-Float 37,7%
Chart CHUGAI PHARMACEUTICAL CO., LTD.
Duration : Period :
Chugai Pharmaceutical Co., Ltd. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends CHUGAI PHARMACEUTICAL CO., LTD.
Short TermMid-TermLong Term
TrendsBullishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 12
Average target price 4 864,75 JPY
Last Close Price 4 931,00 JPY
Spread / Highest target 27,8%
Spread / Average Target -1,34%
Spread / Lowest Target -25,0%
EPS Revisions
Managers
NameTitle
Tatsuro Kosaka Chairman & Chief Executive Officer
Osamu Okuda President, COO & Representative Director
Itagaki Toshiaki CFO, Manager-Information Technology & Accounting
Hisafumi Okabe Senior Executive Officer & Head-Research
Junichi Nezu Executive Officer, GM-Research & Development
Sector and Competitors
1st jan.Capitalization (M$)
CHUGAI PHARMACEUTICAL CO., LTD.46.76%78 704
JOHNSON & JOHNSON2.15%392 249
ROCHE HOLDING AG-4.55%287 762
PFIZER, INC.8.00%222 836
NOVARTIS AG-11.95%206 585
MERCK & CO., INC.-10.45%206 071